All In Biotech

Drug Trial Radar · NCT01586364

Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus

Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus: A 52-Week Open-Label Follow-Up to Protocol 15-50310

Last checked: Nov 20, 2026Latest source record: May 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

301

Actual

Start

May 8, 2006

Primary completion

Nov 21, 2008

Study completion Dec 22, 2008

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
Collaborators
QuatRx Pharmaceuticals
First posted
Apr 26, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study was to assess the long-term safety of daily doses of ospemifene 60 mg in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women without a uterus.

Conditions

  • Atrophy
  • Vaginal Diseases

Interventions

  • Ospemifene 60Mg Oral TabletDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: Week 13 (Phone Contact) to Week 56 (Visit 4)
  2. Change From Baseline in Serum Lipid Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  3. Change From Baseline in Serum Lipid Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  4. Change From Baseline in Blood Pressure at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  5. Change From Baseline in Pulse Rate at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  6. Change From Baseline in Weight at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  7. Change From Baseline in Body Mass Index (BMI) at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  8. Change From Baseline in Blood Pressure at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  9. Change From Baseline in Pulse Rate at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  10. Change From Baseline in Weight at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  11. Change From Baseline in BMI at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  12. Change From Baseline in Visual Evaluation of Vagina at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  13. Change From Baseline in Visual Evaluation of Vagina at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  14. Assessment of Cervical Pap Smear Samples (if Cervix is Intact)Time frame: Week 52 (Visit 3)
  15. Assessment of Breast Palpation at Visit 2Time frame: Week 26 (Visit 2)
  16. Assessment of Breast Palpation at Visit 3Time frame: Week 52 (Visit 3)
  17. Change From Baseline in Coagulation Parameters (Antithrombin Antigen, Protein C Antigen, Protein S Antigen) at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  18. Change From Baseline in Activated Partial Thromboplastin Time (Plasma) at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  19. Change From Baseline in Fibrinogen (Plasma) Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  20. Change From Baseline in Coagulation Parameters (Antithrombin Antigen, Protein C Antigen, Protein S Antigen) at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  21. Change From Baseline in Activated Partial Thromboplastin Time (Plasma) at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  22. Change From Baseline in Fibrinogen (Plasma) Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  23. Change From Baseline in Leukocyte, Lymphocyte, Monocyte and Platelet Count Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  24. Change From Baseline in Erythrocyte Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  25. Change From Baseline in Hemoglobin Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  26. Change From Baseline in Hematocrit and Red Blood Cell (RBC) Distribution Width at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  27. Change From Baseline in Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  28. Change From Baseline in Leukocyte, Lymphocyte, Monocyte and Platelet Count Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  29. Change From Baseline in Erythrocyte Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  30. Change From Baseline in Hemoglobin Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  31. Change From Baseline in Hematocrit and RBC Distribution Width at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  32. Change From Baseline in MCV and MPV at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  33. Change From Baseline in Albumin and Total Protein Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  34. Change From Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Kinase (CK) Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  35. Change From Baseline in Bilirubin, Creatinine, Glucose, Uric Acid and Blood Urea Nitrogen (BUN) Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  36. Change From Baseline in Albumin and Total Protein Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  37. Change From Baseline in ALT, AST and CK Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  38. Change From Baseline in Bilirubin, Creatinine, Glucose, Uric Acid and BUN Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  39. Change From Baseline in pH of Urine at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  40. Change From Baseline in Specific Gravity of Urine at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  41. Change From Baseline in pH of Urine at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  42. Change From Baseline in Specific Gravity of Urine at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  43. Change From Baseline in Estradiol (E2) Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  44. Change From Baseline in Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  45. Change From Baseline in Sex Hormone Binding Globulin (SHBG) Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  46. Change From Baseline in Testosterone Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
  47. Change From Baseline in E2 Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  48. Change From Baseline in FSH and LH Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  49. Change From Baseline in SHBG Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
  50. Change From Baseline in Testosterone Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.